



## Briquilimab, an Anti-CD117 (c-Kit) Antibody, Prevents Cockroach Allergen-Induced Allergic Asthma in Mice Expressing Chimeric Human and Mouse CD117

Mang Yu, Andrew Wells, Sambidhan Kattel, Revati Nerkar, Karl Meneses, Hye-Sook Kwon, and Wendy W. Pang Jasper Therapeutics, Inc., Redwood City, CA





# Mast Cells (MC) play a critical role in allergic inflammation and tissue remodeling in asthma



#### **MC Lung Distribution**

- Airway epithelium
- Submucosal glands
- Airway smooth muscle
- > Alveolar epithelium

#### **MC Pathological Mediators**

- Proteases
- Proteoglycans
- Monoamines
- Neuropeptides
- Lipid mediators
- Cytokines/Chemokines/Growth factors

### **MC** Pathophysiological Effects


- Airway hyperresponsiveness
- > Inflammatory cell infiltration
- Airway barrier damage
- Smooth muscle hypertrophy
- Mucus over production
- Airway remodeling


Galli, et al. Nature (Insight). 2008; 454:445



### Chimeric human/mouse CD117 (h/mCD117) mice Wildtype


B6 mice with h/mCD117 knock-in, replacing endogenous wildtype CD117








# PK characterization of briquilimab in chimeric h/mCD117 mice



- Chimeric h/mCD117 mice received single dose of intravenous briquilimab
- Pharmacokinetic clearance of briquilimab is dose-dependent
- Pharmacokinetic clearance of briquilimab, at all evaluated dose levels, was faster in h/mCD117 mice compared to non-human primates (Kwon *et al*, *Blood*. 2019;133:2104), which is expected due to allometric scaling
- The 25mg/kg briquilimab dose in h/mCD117 mice corresponds to ~2 mg/kg in human, as determined through allometric scaling


#### American Academy of Allergy Asthma & Immunology ANNUAL MEETING WASHINGTON, DC - FEBRUARY 23-26, 2024 Study design: preclinical prophylactic vs. therapeutic models of asthma in h/mCD117 mice




Yu, *et al. J Allergy Clin Immunol*. 2018;142:1618 Briquilimab is an investigational product and not approved for any indication




Prophylactic briquilimab (Briq) treatment inhibits the development of airway inflammation in h/mCD117 mice following cockroach allergen sensitization and challenge







Nineteen days after one-time briquilimab (Briq) preventive treatment, cockroach allergen-sensitized and challenged h/mCD117 mice exhibited significantly decreased numbers of mast cells in the lung and back skin




**PBS** 

Asthma




One-time therapeutic briquilimab (Briq) treatment prevented recurrence of asthma exacerbation following allergen exposure in established asthma models elicited in h/mCD117 mice



Three days post-briquilimab, mice exhibited significantly decreased airway inflammation (including neutrophilic infiltration) and pulmonary resistance following exposure to allergen.



Three days after one-time therapeutic briquilimab (Briq) treatment, established asthma models in h/mCD117 mice exhibited significant decreases in the numbers of mast cells in the lung and back skin following allergen exposure



# **Conclusions & Takeaways**

• Mast cells play a key role in asthma pathophysiology.

American Academy of Allergy Asthma & Immunology

ANNUAL MEETING WASHINGTON, DC - FEBRUARY 23-26, 2024

- Briquilimab can deplete mast cells in both inflamed (lung) and non-inflamed tissue (back skin) in an allergen-induced asthma model elicited in h/mCD117 mice.
- Briquilimab exhibits potential prophylactic and therapeutic benefits in an allergen-induced asthma model elicited in h/mCD117 mice.
- Jasper is actively enrolling participants in a phase 1a/2b trial evaluating briquilimab in patients with chronic spontaneous urticaria (NCT06162728).



## Acknowledgements

## **Jasper Therapeutics**

Edwin Tucker Daniel Adelman Patricia Carlos Ryan Taylor Anne Le Ameer Alameddin Kavitha Arulprakasam Minyoung Youn Song Lee Hind Bouzid



Judy Shizuru Stephen Galli



Meet us at Jasper's booth #444. Copies of the abstract are available on request

